Waters Corporation WAT
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About WAT
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Waters Corporation is a U.S.-based analytical instruments and life sciences company that develops and manufactures technologies used in laboratory analysis, separations science, and materials characterization. The company primarily operates in the analytical instrumentation and diagnostics industries, serving pharmaceutical, biotechnology, industrial, academic, food, environmental, and clinical laboratory customers. Its core revenue drivers include liquid chromatography systems, mass spectrometry instruments, thermal analysis products, consumables, software, and recurring service contracts. Waters is widely recognized for its strength in high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and analytical workflow software.
The company traces its origins to 1958 when James Logan Waters founded Waters Associates in Massachusetts. Waters became publicly traded in 1995 following a spin-off from Millipore Corporation. Over time, the company expanded beyond chromatography into mass spectrometry, thermal analysis, and informatics through internal development and acquisitions. Waters’ strategic positioning is supported by a large installed base of instruments, recurring consumables and service revenue, long-standing relationships with regulated pharmaceutical customers, and strong participation in quality-control and research applications where regulatory compliance and analytical precision are critical.
Business Operations
Waters generates revenue primarily through two major operating platforms: the Waters Division and the TA Instruments Division. The Waters Division includes chromatography systems, mass spectrometry platforms, related consumables, and informatics software used in laboratory workflows. Key product families include ACQUITY UPLC systems, Xevo mass spectrometers, and Empower chromatography data software. The company derives significant recurring revenue from consumables such as columns and chemistry products, as well as instrument service and support agreements. The TA Instruments Division provides thermal analysis, rheology, and calorimetry instruments used in materials science, polymers, batteries, pharmaceuticals, and industrial applications.
The company operates globally across the Americas, Europe, and Asia, with manufacturing, distribution, research, and support functions spanning multiple countries. Waters maintains direct sales and service operations in major scientific markets and also utilizes distributors in select regions. Important subsidiaries include TA Instruments, Vicam, and other regional operating entities supporting diagnostics and analytical testing markets. Waters collaborates with pharmaceutical manufacturers, academic institutions, and laboratory partners to integrate analytical technologies into regulated testing environments and advanced research workflows.
Strategic Position & Investments
Waters’ strategic direction has focused on expanding high-margin recurring revenue, increasing penetration in biopharmaceutical analysis, and strengthening capabilities in mass spectrometry and laboratory informatics. The company has invested heavily in next-generation analytical platforms designed for biologics characterization, gene therapy research, and advanced materials testing. Waters has also emphasized software integration and workflow automation to support regulatory compliance and laboratory efficiency for pharmaceutical and industrial customers.
The company has pursued acquisitions and portfolio investments that extend its analytical technologies and market reach. Notable acquisitions include TA Instruments, which broadened Waters’ presence in materials characterization, and Andrew Alliance, which added laboratory automation and collaborative robotics capabilities. Waters has also invested in technologies related to biologics analysis, precision medicine workflows, and data-driven laboratory operations. Its strategic positioning benefits from long product cycles, high switching costs in regulated environments, and continued global demand for analytical testing in pharmaceuticals, food safety, and environmental monitoring.
Geographic Footprint
Waters Corporation is headquartered in Milford, Massachusetts, and operates across major scientific and industrial markets worldwide. The company maintains a significant presence in North America, Europe, and Asia-Pacific, with international operations contributing a substantial majority of total revenue according to recent public filings. Key markets include the United States, China, Japan, India, Germany, the United Kingdom, France, and other regions with strong pharmaceutical and industrial research activity.
The company supports customers through global manufacturing facilities, technical support centers, distribution networks, and research operations. Waters has established a particularly strong commercial footprint in pharmaceutical manufacturing hubs and research-intensive regions. Its international reach is reinforced by localized sales and service teams that support regulated laboratories, academic research institutions, and industrial quality-control operations across multiple continents.
Leadership & Governance
Waters Corporation is governed by a board of directors and executive leadership team focused on scientific innovation, operational execution, and long-term shareholder returns. The company’s leadership strategy has emphasized disciplined capital allocation, expansion in high-growth analytical markets, and increased recurring revenue through services and consumables. Public company governance practices are outlined in annual filings including the company’s SEC Form 10-K and proxy statements.
Key executives include:
- Udit Batra – President and Chief Executive Officer
- Amol Chaubal – Senior Vice President and Chief Financial Officer
- Dr. Ian King – Vice President, Global Research and Development
- Christopher O’Connell – Chairman of the Board
- Rohit Khanna – Senior Vice President, Global Markets
- Stéphane Kasriel – Board Member
Leadership commentary in public filings and investor communications has consistently emphasized innovation in analytical science, customer workflow integration, operational efficiency, and expansion in pharmaceutical and biologics testing markets.